Skip to Main content Skip to Navigation
Journal articles

Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?

Abstract : In Parkinson’s disease (PD) depletion of dopamine in the nigro-striatal pathway is a main pathological hallmark that requires continuous and focal restoration. Current predominant treatment with intermittent oral administration of its precursor, Levodopa (L-dopa), remains the gold standard but pharmacological drawbacks trigger motor fluctuations and dyskinesia. Continuous intracerebroventricular (i.c.v.) administration of dopamine previously failed as a therapy because of an inability to resolved the accelerated dopamine oxidation and tachyphylaxia. We aim to overcome prior challenges by demonstrating treatment feasibility and efficacy of continuous i.c.v. of dopamine close to the striatum. Dopamine prepared either anaerobically (A-dopamine) or aerobically (O-dopamine) in the presence or absence of a conservator (sodium metabisulfite, SMBS) was assessed upon acute MPTP and chronic 6-OHDA lesioning and compared to peripheral L-dopa treatment. A-dopamine restored motor function and induced a dose dependent increase of nigro-striatal dopaminergic neurons in mice after 7 days of MPTP insult that was not evident with either O-dopamine or L-dopa. In the 6-OHDA rat model, continuous circadian i.c.v injection of A-dopamine over 30 days also improved motor activity without occurrence of tachyphylaxia. This safety profile was highly favorable as A-dopamine did not induce dyskinesia or behavioral sensitization as observed with peripheral L-dopa treatment. Indicative of a new therapeutic strategy for patients suffering from L-dopa related complications with dyskinesia, continuous i.c.v of A-dopamine has greater efficacy in mediating motor impairment over a large therapeutic index without inducing dyskinesia and tachyphylaxia.
Document type :
Journal articles
Complete list of metadata

Cited literature [30 references]  Display  Hide  Download
Contributor : David Devos Connect in order to contact the contributor
Submitted on : Monday, April 3, 2017 - 2:52:24 PM
Last modification on : Wednesday, March 23, 2022 - 3:51:22 PM
Long-term archiving on: : Tuesday, July 4, 2017 - 12:55:03 PM


Dive paper.pdf
Files produced by the author(s)




Charlotte Laloux, Flore Gouel, Cédrick Lachaud, Kelly Timmerman, Bruce Do Van, et al.. Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?. Neurobiology of Disease, Elsevier, 2017, ⟨10.1016/j.nbd.2017.03.013⟩. ⟨inserm-01500610⟩



Record views


Files downloads